These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38902191)

  • 1. Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups.
    Li M; Chen W; Deng Y; Xie W
    Nutr Metab Cardiovasc Dis; 2024 Sep; 34(9):2085-2094. PubMed ID: 38902191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score.
    Sripongpun P; Kaewdech A; Udompap P; Kim WR
    JHEP Rep; 2024 Oct; 6(10):101127. PubMed ID: 39290401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
    Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence.
    Ciardullo S; Mantovani A; Morieri ML; Muraca E; Invernizzi P; Perseghin G
    Liver Int; 2024 Aug; 44(8):1762-1767. PubMed ID: 38597738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.
    Kim D; Wijarnpreecha K; Cholankeril G; Ahmed A
    Aliment Pharmacol Ther; 2024 Jul; 60(1):33-42. PubMed ID: 38649335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease.
    Chen Q; Hu P; Hou X; Sun Y; Jiao M; Peng L; Dai Z; Yin X; Liu R; Li Y; Zhu C
    Cardiovasc Diabetol; 2024 Jul; 23(1):232. PubMed ID: 38965572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake.
    Aboona MB; Danpanichkul P; Chen VL; Rangan P; Kim D; Alkhouri N; Fallon MB; Noureddin M; Arab JP; Wijarnpreecha K
    J Gastroenterol Hepatol; 2024 Aug; ():. PubMed ID: 39175201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
    Marti-Aguado D; Calleja JL; Vilar-Gomez E; Iruzubieta P; Rodríguez-Duque JC; Del Barrio M; Puchades L; Rivera-Esteban J; Perelló C; Puente A; Gomez-Medina C; Escudero-García D; Serra MA; Bataller R; Crespo J; Arias-Loste MT
    J Hepatol; 2024 Jul; ():. PubMed ID: 38971533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
    Kwak M; Kim HS; Jiang ZG; Yeo YH; Trivedi HD; Noureddin M; Yang JD
    Hepatology; 2024 May; ():. PubMed ID: 38739848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
    Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
    Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term risk of cardiovascular disease associated with MASLD and different cardiometabolic risk factors in IBD patients: A prospective cohort study.
    Zhang Q; Xu F; Liu S; Zhu S; Zhang S; Wu J; Wu S
    Liver Int; 2024 Sep; 44(9):2315-2328. PubMed ID: 38819640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight-adjusted waist index is positively and linearly associated with all-cause and cardiovascular mortality in metabolic dysfunction-associated steatotic liver disease: findings from NHANES 1999-2018.
    Liu W; Yang X; Zhan T; Huang M; Tian X; Tian X; Huang X
    Front Endocrinol (Lausanne); 2024; 15():1457869. PubMed ID: 39403588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease.
    Chen YT; Chen TI; Yin SC; Huang CW; Huang JF; Lu SN; Yeh ML; Huang CF; Dai CY; Chen YW; Chuang WL; Yu ML; Lee MH
    J Gastroenterol Hepatol; 2024 Sep; 39(9):1939-1949. PubMed ID: 38725327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
    Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
    Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease.
    Min Y; Wei X; Wei Z; Song G; Zhao X; Lei Y
    Cardiovasc Diabetol; 2024 Jun; 23(1):188. PubMed ID: 38824550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality.
    Oh R; Kim S; Cho SH; Kim J; Lee YB; Jin SM; Hur KY; Kim G; Kim JH
    Diabetes Metab J; 2024 Aug; ():. PubMed ID: 39197834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population.
    Männistö V; Salomaa V; Jula A; Lundqvist A; Männistö S; Perola M; Åberg F
    JHEP Rep; 2024 Oct; 6(10):101172. PubMed ID: 39430577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality.
    Kim D; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A
    J Gastroenterol Hepatol; 2024 Sep; 39(9):1950-1956. PubMed ID: 38740513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.